EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pretreatment stromal CD4⁺ T-cell density predicts favorable response to total neoadjuvant therapy in locally advanced rectal cancer

Hatice Telci, Sabin Goktas Aydin, Taskın Erkinuresin, Sinan Can Tasan, Enes Ozluk, Emre Bozdag, Fatma Sahin, Erkan Somuncu

Biomolecules and Biomedicine · 17.07.2026

DOI: 10.17305/bb.2026.14270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 17.07.2026. Verfasst von Hatice Telci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Istanbul SBU Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Türkiye. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Total neoadjuvant therapy (TNT) has become an important treatment strategy for locally advanced rectal cancer (LARC), increasing the need for pretreatment biomarkers that may predict major tumor response and support organ-preserving approaches. This study aimed to evaluate whether pretreatment stromal CD4⁺ and CD8⁺ T-cell densities, together with stromal tumor-infiltrating lymphocytes (TILs), are associated with response to TNT in patients with LARC. In this retrospective study, 45 patients with LARC who completed TNT were analyzed; pretreatment colonoscopic biopsy specimens were available for all patients, and paired post-treatment resection specimens were available for 40 surgically treated patients. CD4⁺ and CD8⁺ T-cell densities were assessed immunohistochemically in stromal hotspot areas and expressed as cells/mm², while stromal TILs were evaluated on hematoxylin–eosin sections. A favorable response was defined as tumor regression grade (TRG) 0–1 in surgically treated patients or clinical complete response in patients managed with a watch-and-wait strategy. Median pretreatment CD4⁺ T-cell density, CD8⁺ T-cell density, and stromal TIL percentage were 320 cells/mm², 64 cells/mm², and 30%, respectively. Receiver operating characteristic (ROC) analysis identified a pretreatment stromal CD4⁺ T-cell density cutoff of 410 cells/mm² for favorable response, with an area under the curve (AUC) of 0.68 (p=0.041). CD4⁺ T-cell density >410 cells/mm² was significantly associated with favorable response and remained independently associated with response in multivariable logistic regression analysis (odds ratio [OR]=5.05, 95% confidence interval [CI]: 1.21–20.83, p=0.026). In contrast, pretreatment CD8⁺ T-cell density and stromal TIL percentage were not significantly associated with response. In paired specimens, CD8⁺ T-cell density increased significantly after treatment (p

Autor:innen und Institutionen

  • Department of General Surgery, Istanbul SBU Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Türkiye.
  • Department of Medical Oncology, Istanbul SBU Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Türkiye.
  • Department of Pathology, Istanbul SBU Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Türkiye.
  • Department of Radiology, Istanbul SBU Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Türkiye.

Zitieren

APA

Telci, H., Goktas Aydin, S., Erkinuresin, T., Tasan, S. C., Ozluk, E., Bozdag, E., Sahin, F., & Somuncu, E. (2026). Pretreatment stromal CD4⁺ T-cell density predicts favorable response to total neoadjuvant therapy in locally advanced rectal cancer. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2026.14270

Vancouver

Telci H, Goktas Aydin S, Erkinuresin T, Tasan SC, Ozluk E, Bozdag E, et al. Pretreatment stromal CD4⁺ T-cell density predicts favorable response to total neoadjuvant therapy in locally advanced rectal cancer. Biomolecules and Biomedicine. 2026. doi:10.17305/bb.2026.14270

BibTeX
@article{Telci2026,
  author = {Telci, Hatice and Goktas Aydin, Sabin and Erkinuresin, Taskın and Tasan, Sinan Can and Ozluk, Enes and Bozdag, Emre and Sahin, Fatma and Somuncu, Erkan},
  title = {Pretreatment stromal CD4⁺ T-cell density predicts favorable response to total neoadjuvant therapy in locally advanced rectal cancer},
  journal = {Biomolecules and Biomedicine},
  year = {2026},
  doi = {10.17305/bb.2026.14270}
}
Kostenlos starten →